Risk of venous thromboembolism among users of different anti-osteoporosis drugs: a population-based cohort analysis including over 200,000 participants from Spain and the UK-Reference-Cited by-同舟云学术

Risk of venous thromboembolism among users of different anti-osteoporosis drugs: a population-based cohort analysis including over 200,000 participants from Spain and the UK

Published:2017-12-03 Issue:2 Volume:29 Page:467-478
ISSN:0937-941X
Container-title:Osteoporosis International
language:en
Short-container-title:Osteoporos Int

Author:

Martín-Merino E.^ORCID,Petersen I.,Hawley S.,Álvarez-Gutierrez A.,Khalid S.,Llorente-Garcia A.,Delmestri A.,Javaid M. K.,Van Staa T. P.,Judge A.,Cooper C.,Prieto-Alhambra D.

Funder

National Osteoporosis Society

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology, Diabetes and Metabolism

Link

http://link.springer.com/article/10.1007/s00198-017-4308-5/fulltext.html

Reference30 articles.

1. European Medicines Agency. Protelos. Background information on the procedure [Internet]. 2005 [cited 2017 Mar 13]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Procedural_steps_taken_before_authorisation/human/000560/WC500045523.pdf

2. European Medicines Agency. CHMP Type II variation assessment report. Invented name Protelos. Procedure No. EMEA/H/C/000560/II/0031 [Internet]. 2012 May [cited 2017 Mar 13]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000560/WC500131790.pdf

3. European Medicines Agency. PSUR assessment report. Strontium ranelate. EMA/PRAC/136656/2013 [Internet]. 2013 [cited 2016 Jun 23]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000560/WC500147168.pdf

4. European Medicines Agency. Assessment report for Protelos and Osseor. Review under Article 20 of Regulation (EC) No 726/2004 [Internet]. 2012 May [cited 2016 Jun 23]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000561/WC500131785.pdf

5. European Medicines Agency. Protelos and Osseor-CHMP scientific conclusions and PRAC Assessment report of the Review under Article 20 of Regulation (EC) No 726/2004 [Internet]. 2014 [cited 2017 Mar 13]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Conclusion/human/000560/WC500169913.pdf

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Effects of the Addition of Strontium on the Biological Response to Calcium Phosphate Biomaterials: A Systematic Review;Applied Sciences;2024-08-27

2. PMAIP1, a novel diagnostic and potential therapeutic biomarker in osteoporosis;Aging;2024-02-16

3. Application of Micro-computed Tomography in the Microstructure of Cervical Uncinate Processes Trabecular Bone;2023-09-12

4. The Role of m6A in Osteoporosis and the Differentiation of Mesenchymal Stem Cells into Osteoblasts and Adipocytes;Current Stem Cell Research & Therapy;2023-04

5. Curator – A data curation tool for clinical real-world evidence;Informatics in Medicine Unlocked;2023